Abstracts tagged "Neutropenia and rituximab"

Abstract Number: 1562 • 2018 ACR/ARHP Annual Meeting
Large Granular Lymphocyte Proliferations in Primary Sjögren’s Syndrome: An Iatrogenic Manifestation
Alistair Baber¹, Gaetane Nocturne², Xavier Mariette³ and Raphaele Seror⁴, ¹Rheumatology, Université Paris-Sud, Le Kremlin-Bicêtre, France, ²Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ³Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France, ⁴Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Rheumatology, Université Paris Sud, Le Kremlin Bicetre, France
Background/Purpose: Large granular lymphocyte (LGL) proliferations can be observed in some auto-immune disorders, especially rheumatoid arthritis. However, reports of LGL proliferations in primary Sjogren’s syndrome…
Abstract Number: 450 • 2012 ACR/ARHP Annual Meeting
Late Onset Neutropenia After Rituximab Treatment for Rheumatological Conditions
Gabriel S. Breuer¹, Michael Z. Ehrenfeld², Itzhak Rosner³, Alexandra Balbir-Gurman⁴, Devy Zisman⁵ and Daphna Paran⁶, ¹Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ²Dept of Med C & Rheum Dis Unit, Chaim Sheba Medical Center, Tel HaShomer, Israel, ³Rheumatology, Bnai Zion Medical Center / Technion Faculty of Medicine, Haifa, Israel, ⁴B. Shine Rheumatology Unit, Rambam Health Care Campus, Bruce, Haifa, Israel, ⁵Dept of Internal Medicine, Carmel Medical Center, Haifa, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel Aviv, Israel
Background/Purpose: Rituximab is a monoclonal chimeric antibody targeting the CD20 on the surface of normal and abnormal maturing B cells. Late onset neutropenia (LON) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].